First GLP‑1 pill approved
The FDA approved oral semaglutide as the first GLP‑1 pill for weight loss, creating a non‑injectable option for people with obesity and overweight. (ajmc.com) Separately, Eli Lilly says it plans to launch its oral GLP‑1 candidate orforglipron in 40 countries, including India, once approvals are in place. (news9live.com)
A glucagon-like peptide 1 drug copies a gut hormone that helps people feel full, and on April 1 the Food and Drug Administration approved the first weight-loss version in pill form. (fda.gov) The new product is Wegovy tablets, an oral form of semaglutide, for adults with obesity or adults with overweight plus at least one weight-related condition, alongside diet and physical activity. The same Food and Drug Administration label also says the tablets are approved to cut the risk of major cardiovascular events in adults with cardiovascular disease and obesity or overweight. (fda.gov) Until now, semaglutide for weight loss in the United States was sold as a weekly shot, and the Food and Drug Administration approved a higher-dose Wegovy injection, called Wegovy HD, on March 19, 2026. That approval came 54 days after filing under the agency’s Commissioner’s National Priority Voucher pilot program. (fda.gov) Pills and shots work differently for patients even when the active ingredient is similar. Lilly said its newly approved oral obesity drug, Foundayo, the brand name for orforglipron, can be taken any time of day without food or water restrictions and began shipping in the United States after its April 1, 2026 approval. (lilly.com) Lilly also said on February 26, 2026 that it had submitted orforglipron to regulators in more than 40 countries. In that same announcement, the company reported a 52-week head-to-head diabetes trial in 1,698 adults in which the 36 milligram dose cut weight by 19.7 pounds, compared with 11.0 pounds for oral semaglutide 14 milligrams. (lilly.com) The semaglutide tablet label carries the same core warnings already familiar from injectable glucagon-like peptide 1 drugs. The Food and Drug Administration says Wegovy carries a boxed warning about thyroid C-cell tumors seen in rodents and should not be used in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. (fda.gov) Lilly reported average weight loss of 27.3 pounds, or 12.4%, at the highest Foundayo dose among participants who stayed on treatment in the ATTAIN-1 trial. The company said self-pay prices start at $149 a month at the lowest dose, while some commercially insured patients may pay as little as $25 a month. (lilly.com) The new question is no longer whether an obesity drug can come as a pill. The question is which pill patients can get, what restrictions come with it, and how quickly regulators outside the United States clear the next launches. (fda.gov)
